Helex

Biotechnology Research • Manhattan, New York, United States • 21-50 Employees

Company overview

Headquarters	180 Varick St, New York, NY 10014, US
Website	helex.bio
Keywords	Renal Disease, Lipid Nanoparticle, Gene Editing, Epigenetics, Genomic Medicines, Cell Specific Editing, Genetic Medicines Drug Design, Nonviral Delivery
Founded	2021
Employees	21-50
Socials

Key Contacts at Helex

Rohini Kalvakuntla

Co-Founder

Bernice Khor

Director Of Studies

Britta Stoltz Lundström

Owner

Helex Email Formats

Helex uses 3 email formats. The most common is {first initial} (e.g., j@helex.bio), used 40% of the time.

Format	Example	Percentage
{first initial}	j@helex.bio	40%
{first name}.{last name}	john.doe@helex.bio	40%
{first initial}.{last name}	j.doe@helex.gr	20%

About Helex

Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure(TM) 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.

Helex revenue & valuation

Annual revenue	$1,882,210
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$6,100,000
Total funding	No funding